Ireland
--:--IST
Latest
Clinical Trials in Italy / NCT04295252
Recruiting Observational

Altshock-2 REGISTRY

NCT04295252 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2020-07-01
Last updated
2026-05-14

Condition(s) studied

Cardiogenic Shock

Study summary

The study will provide data on profile, management, outcome, and evolution over time of cardiogenic shock patients admitted to the Intensive Coronary Care Units

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
All consecutive CS patients hospitalized in the above reported centres between January 2020 and December 2030. Cardiogenic shock is defined as: 1. Systolic blood pressure (SBP) \<90 mmHg or mean arterial pressure (MAP) \<60 mmHg, after an appropriate fluid challenge if there is no sign of overt fluid overload, OR need of vasoactive agents to maintain SBP \> 90 mmHg or MAP \> 60 mmHg, OR need of MCS; 2. At least one of the following criteria/signs of overt hypoperfusion: mixed venous oxygen saturation \<60%; arterial lactates \> 2 mmol/L; oliguria \< 0.5 ml/Kg/h for at least 6 hours.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ASST GOM Niguarda Milan Italy Recruiting

More Niguarda Hospital trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04295252 on ClinicalTrials.gov ↗ ← All trials in Italy